

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>ARCH Venture Partners XII, LLC</u>  (Last) (First) (Middle) 8755 W. HIGGINS ROAD, SUITE 1025  (Street) CHICAGO IL 60631  (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Neumora Therapeutics, Inc. [ NMRA ]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director <input checked="" type="checkbox"/> 10% Owner  Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) 11/13/2023	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	
Rule 10b5-1(c) Transaction Indication  <input type="checkbox"/> Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.		

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	11/13/2023		P		31,653	A	\$11.75 <sup>(1)</sup>	4,127,850	I	By ARCH Venture Fund XII, L.P. (3)(4)
Common Stock	11/14/2023		P		3,357	A	\$11.98 <sup>(2)</sup>	4,131,207	I	By ARCH Venture Fund XII, L.P. (3)(4)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date					

1. Name and Address of Reporting Person\*  
ARCH Venture Partners XII, LLC  
 (Last) (First) (Middle)  
 8755 W. HIGGINS ROAD, SUITE 1025  
 (Street)  
 CHICAGO IL 60631  
 (City) (State) (Zip)

1. Name and Address of Reporting Person\*  
ARCH Venture Partners XII, L.P.  
 (Last) (First) (Middle)  
 8755 W. HIGGINS ROAD, SUITE 1025  
 (Street)  
 CHICAGO IL 60631

(City)	(State)	(Zip)
1. Name and Address of Reporting Person*		
<a href="#">ARCH Venture Fund XII, L.P.</a>		
(Last)	(First)	(Middle)
8755 W. HIGGINS ROAD, SUITE 1025		
(Street)		
CHICAGO	IL	60631
(City)	(State)	(Zip)
1. Name and Address of Reporting Person*		
<a href="#">CRANDELL KEITH</a>		
(Last)	(First)	(Middle)
8755 WEST HIGGINS ROAD, SUITE 1025		
(Street)		
CHICAGO	IL	60631
(City)	(State)	(Zip)
1. Name and Address of Reporting Person*		
<a href="#">GILLIS STEVEN</a>		
(Last)	(First)	(Middle)
8755 WEST HIGGINS ROAD, SUITE 1025		
(Street)		
CHICAGO	IL	60631
(City)	(State)	(Zip)
1. Name and Address of Reporting Person*		
<a href="#">NELSEN ROBERT</a>		
(Last)	(First)	(Middle)
8755 W. HIGGINS ROAD, SUITE 1025		
(Street)		
CHICAGO	IL	60631
(City)	(State)	(Zip)

**Explanation of Responses:**

1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from \$11.52 to \$12.00, inclusive. The reporting person undertakes to provide to NMRA, any security holder of NMRA, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4.
2. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from \$11.89 to \$12.00, inclusive.
3. Beneficial ownership consists of 4,131,207 shares of common stock held directly by ARCH Venture Fund XII, L.P. (ARCH XII). ARCH Venture Partners XII, L.P. (AVP XII LP) is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (AVP XII LLC) is the general partner of AVP XII LP. Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP XII LLC (the AVP XII LLC Committee Members). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any.
4. As of the date hereof, in addition to securities owned by AVF XII, the investment committee members continue to have an indirect pecuniary interest in securities of the issuer as reported on a Form 4 filed by the reporting persons with respect to the issuer on September 20, 2023.

**Remarks:**

This Form 4 is filed jointly by ARCH XII, AVP XII LP, AVP XII LLC, Robert Nelsen, Steven Gillis, Keith Crandell (collectively, the "Reporting Persons"). Kristina Burow has direct ownership of common stock and is filing her own Form 4 separately.

[ARCH Venture Fund XII, L.P.](#)  
 By: [ARCH Venture Partners XII, L.P., its General Partner](#)  
 By: [ARCH Venture Partners XII, LLC, its General Partner](#) 11/15/2023  
 By: [/s/ Mark McDonnell, as Attorney-in-Fact](#)  
[ARCH Venture Partners XII, L.P. By: ARCH Venture Partners XII, LLC, its General Partner](#) By: [/s/ Mark McDonnell, as Attorney-in-Fact](#) 11/15/2023

<u>ARCH Venture Partners XII, LLC By: /s/ Mark McDonnell, as Attorney-in-Fact</u>	<u>11/15/2023</u>
<u>Keith Crandell, Managing Director, By: /s/ Mark McDonnell, as Attorney-in-Fact</u>	<u>11/15/2023</u>
<u>Steven Gillis, Managing Director, By: /s/ Mark McDonnell, as Attorney-in-Fact</u>	<u>11/15/2023</u>
<u>Robert Nelsen, Managing Director, By: /s/ Mark McDonnell, as Attorney-in-Fact</u>	<u>11/15/2023</u>
** Signature of Reporting Person	Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**